Compare
Neurocrine Biosciences Inc vs Exelixis, Inc. vs Qiagen N.V. vs Moderna, Inc.
| Latest fiscal year | Neurocrine Biosciences Inc NBIX | Exelixis, Inc. EXEL | Qiagen N.V. QGEN | Moderna, Inc. MRNA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-01-02 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.86B | $2.32B | $2.09B | $1.94B |
| Revenue growth (YoY) | +21.4% | +7.0% | +5.7% | -39.9% |
| Gross margin | n/a | n/a | 62.2% | 55.3% (computed) |
| Operating margin | 21.6% | 37.6% | 22.3% | -158.1% |
| Net margin | 16.7% | 33.7% | 20.3% | -145.2% |
| Net income | $478.60M | $782.57M | $424.88M | -$2.82B |
| EPS (Diluted) | $4.67 | $2.78 | $1.94 | -$7.26 |
| Operating cash flow | $782.70M | $884.27M | $654.33M | -$1.87B |
| Free cash flow | $748.70M | $875.84M | $453.28M | -$2.06B |
| Cash & equivalents | $713.00M | $482.49M | $839.00M | $2.60B |
| Total assets | $4.63B | $2.84B | $6.28B | $12.34B |
| Total liabilities | $1.38B | $683.10M | n/a | $3.69B |
| Shareholders' equity | $3.25B | $2.16B | $3.78B | $8.65B |
| Return on year-end equity | 14.7% | 36.2% | 11.2% | -32.6% |
| Shares outstanding | 100.10M | 262.48M | n/a | 394.00M |
Revenue, most recent five fiscal years
| Fiscal year | Neurocrine Biosciences Inc | Exelixis, Inc. | Qiagen N.V. | Moderna, Inc. |
|---|---|---|---|---|
| Latest | $2.86B Ended 2025-12-31 | $2.32B Ended 2026-01-02 | $2.09B Ended 2025-12-31 | $1.94B Ended 2025-12-31 |
| 1 year earlier | $2.36B Ended 2024-12-31 | $2.17B Ended 2025-01-03 | $1.98B Ended 2024-12-31 | $3.24B Ended 2024-12-31 |
| 2 years earlier | $1.89B Ended 2023-12-31 | $1.83B Ended 2023-12-29 | $1.97B Ended 2023-12-31 | $6.85B Ended 2023-12-31 |
| 3 years earlier | $1.49B Ended 2022-12-31 | $1.61B Ended 2022-12-30 | $2.14B Ended 2022-12-31 | $19.26B Ended 2022-12-31 |
| 4 years earlier | $1.13B Ended 2021-12-31 | $1.43B Ended 2021-12-31 | $2.25B Ended 2021-12-31 | $18.47B Ended 2021-12-31 |